cantly worse prognosis, with higher mortality and complication rates than for younger individuals (3, 29, 32) , suggesting that age-associated changes in the cardiovascular system may predispose older individuals to increased vascular pathology. Previous studies (33, 37) have demonstrated that altered regulation and dysfunction of vascular endothelial cells is linked to worsened clinical outcomes in cardiovascular disease. In vivo physiology studies reveal that aging results in endothelial and vascular dysfunction with impaired vascular relaxation and changes in angiogenic pathways and coagulation factors (for review, see Ref. 41) . Recently, we (10) demonstrated that age-associated impairment of the platelet-derived growth factor (PDGF)-B induction pathway in cardiac microvascular endothelial cells (CMECs) contributes to the dysregulation of cardiac vascular function in the older rodent models. Restoration of this pathway through delivery of PDGF-AB is cardioprotective, reducing the extent of myocardial injury after coronary occlusion.
Previous studies (31, 34, 40) have shown that aging is associated with significant alterations in the expression patterns of cell surface cytokine receptors, thus suggesting a potential mechanism that may contribute to senescent changes in cardiac microvasculature activity. Our study is aimed at defining the molecular pathways that underlie the age-associated impairment of cardiovascular function. Here we report the results of in vivo cyclic peptide phage display library biopanning studies that identified an age-associated alteration in cardiac microvascular endothelial tumor necrosis factor-␣ (TNF-␣) receptor pathways that can contribute to the senescent impairment in PDGF-B induction and loss of cardioprotection.
MATERIALS AND METHODS
All of the experiments involving animals were performed in accordance with the Institutional Animal Care and Use Committee of the Weill Medical College of Cornell University, which follows Federal and state guidelines.
Phage-Display Peptide Library In Vivo Cardiac Vascular Biopanning. The age-associated changes in cardiac microvascular surface receptors were probed by in vivo phage-display biopanning with a cyclic peptide pSKAN phagemid library (6 amino acid variable; ϳ10 7 total complexity, Mo Bio Tech). Young adult (3 mo old) and aging (18 mo old) C57B61/L mice were anesthetized with 0.015 ml/g Avertin and injected with phage peptide library phage [10 12 colony forming units (CFU)/200 l PBS] via the tail veins. Four minutes after injection, the mice were euthanized, the hearts explanted, and the phage recovered with WK6mutS Escherichia coli. Age-specific phage pools were amplified and titrated for two additional rounds of biopanning enrichment. The phagemid DNA of the resultant clones were sequenced and translated amino acid motifs determined employing read through of all codons, as previously described for phage display library analysis (6, 13) . Translated motifs were analyzed for homology to known cytokines (FASTA3), as determined by the first homologous mammalian sequence identified with E value Ͻ1. In addition, to probe the structural relevance of the phage motif cytokine binding epitopes, the regions of homology were mapped in the tertiary models and labeled by Cn3D3.0 software.
Individual phage clone in vivo cardiac vascular biopanning. To confirm the age-associated differential cardiac binding capacity of a candidate phage with homology to TNF-␣, phage clone ⌿Y12, as well as helper phage without the insert, were prepared with TG1 E. coli to generation of phage motifs with supE suppression, as previously described (6) . The ⌿Y12 phage (10 12 CFU in 200 l PBS) was injected into both 3-and 18-mo-old mice, as described above (n ϭ 3, each group). The phages were recovered from the explanted hearts, as described above, with WK6mutS E. coli, which were then quantified by serial dilution titration.
In situ cardiac TNF-␣ receptor analysis. On the basis of the homology of ⌿Y12 to TNF-␣, the potential age-associated changes in TNF-␣ receptor patterns were analyzed in situ. Cardiac sections of 3-and 18-mo-old wild-type mice were probed with goat antibodies directed against TNF-receptors 1 and 2 (TNF-R1 and -R2; Santa Cruz, Sc1079 and 1074) and developed with an anti-goat ABC kit with diaminobenzidine (Vector). Immunostained vascular density was quantified in the subendocardial tissue, as previously described: 16 highpower fields magnified ϫ40 per heart (n ϭ 3, each group) (10) . Counts were performed by two investigators in a blinded fashion.
TNF-␣ induction of PDGF-B in CMECs. The potential age-associated impairment in TNF-␣-mediated induction of cardiac endothelial PDGF-B expression was measured in vitro. CMECs of 4-and 24-mo-old F344 rats were isolated and cultured, as previously described (26), with minor modification. Briefly, the hearts were removed and minced in endothelial cell medium; DMEM containing 20% FBS, 1% endothelial cell growth factor, 1% endothelial cell growth supplement, 1% basal medium Eagle, 10 Ϫ4 % heparin, and 1% penicillin (10,000 IU/ml streptomycin 10,000 g/ml) and digested with the addition of 0.2% collagenase, 0.005% DNAse, and 5% FBS for 45 min with subsequent endothelial cells isolation by platelet endothelial cell adhesion moleculemediated magnetic particle collection (Dynabeads), as detailed earlier (7) . The resultant CMECs (Dil-LDL uptake Ͼ95%) were cultured for two passages and seeded into 12-well culture dish (10 5 cell/well) and grown to confluence. The medium was changed to serum-free DMEM for 1 h and then to DMEM with 2% FBS Ϯ TNF-␣ (30 ng/ml) for 3 h. Total RNA was then isolated and RT-PCR performed, as previously described (10) . The primers for PCR were listed as follows: rat PDGF-B (sense) 5Ј-GATCCGCTCCTTTGATGATC-3Ј; rat PDGF-B (antisense) 5Ј-GTCTCACACTTGCATGCCAG-3Ј; rat ␤-actin (sense) 5Ј-ATTGGCAATGAGCGGTTCCGC-3Ј; and rat ␤-actin (antisense) 5Ј-CTCCTGCTTGCTGATCCA-CATC-3Ј.
Age-dependent in vivo response to TNF-␣. To probe the potential age-dependent effects of TNF-␣ on PDGF-B expression and protection from myocardial injury, sets of 4-and 24-mo-old F344 rats received intramyocardial injections of the growth factor, as previously described (10) . Briefly, the rats were anesthetized with xylazine (5-10 mg/kg ip) and ketamine (80-90 mg/kg ip) and underwent a left intercostal thoracotomy. After the left anterior descending coronary artery (LAD) was identified, 100 ng of TNF-␣ in 50 l PBS or PBS alone were injected through a 30 gauge needle, using a 250-l Hamilton syringe. Two injections (25 l/injection 2 mm apart) were made at the middle left ventricular anterior wall. The chest wall was then closed, the lungs were inflated, the rat was extubated, and the tracheotomy was closed.
Age-dependent TNF-␣-mediated induction of PDGF-B.
Rats receiving pretreatments alone (TNF-␣ or PBS control, 4-and 24-mo-old, n ϭ 3 each group) were euthanized 24 h postinjection. The hearts were excised, fixed, sectioned, and immunostained for PDGF-B (murine anti-PDGF-B, 376M, BioGenex) and visualized with a Texas red conjugated donkey anti-mouse antibody (Sc2785, Santa Cruz). PDGF-B staining was quantified in the subendocardial tissue in the anterior left ventricular wall at the level of the midpapillary muscles from each heart by identifying all PDGF-B-stained luminal structures, as previously described (10) (8 highpower fields magnified ϫ40 per heart). Two investigators performed quantification independently in a blinded fashion.
Age-specific TNF-␣-mediated protection from myocardial infarction. The potential cardioprotective effects of TNF-␣ pretreatments were studied in a myocardial infarction model. One day after TNF-␣ (4 mo old, n ϭ 4; 24 mo old, n ϭ 10) or control (4 mo old, n ϭ 4; 24 mo old, n ϭ 10) intramyocardial injections, the rats were anesthetized, the heart was exposed, and the LAD was ligated just below (4 mo old) or 2 mm below (24 mo old) the left atrial appendage with 8-0 nylon sutures. Pallor and regional wall motion abnormality of the left ventricle confirmed occlusion. The chest wall was closed, and, after recovery, the rats were returned to the animal facility and kept for 14 days. The rats were killed and Fig. 1 . In vivo peptide phage biopanning identification of aging-associated changes in cardiac microvascular epitope binding. A: the young heart homing phage (⌿Y12) epitope sequence with homology to tumor necrosis factor-␣ (TNF-␣). B: three-dimensional structure of TNF-␣ with homology to ⌿Y12 highlighted in yellow. C: quantification of ⌿Y12 binding in the young and old hearts measured by titers of phage eluted from 3-and 18-mo-old hearts of mice receiving tail vein injections of ⌿Y12 phage or helper phage (without peptide insert) (n ϭ 3, each). CFU, colony-forming units. *P Ͻ 0.05 3-vs. 18-mo-old hearts. S-S, disulfide bond. the hearts were harvested, fixed, and sectioned. Myocardial infarction size measured at the level of the midpapillary heart muscles was scored by Masson's trichrome staining (20, 30) , and the images were analyzed in a blinded fashion employing NIH Image Software version J1.22 (27, 38) . Infarction size was expressed as a percentage of the total left ventricle myocardial area. Cardiac samples from aging rats that expired within 72 h of TNF-␣ injection were sectioned and analyzed for apoptotic induction by terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling staining (in situ cell death kit no. 684817, Roche) (n ϭ 3). To measure the potential interactions of TNF-␣ and PDGF-AB, sets of rats were treated with a combination of TNF-␣ (100 ng/heart) and PDGF-AB (100 ng/heart) in 4-mo-old rats (n ϭ 5) and 24-mo-old rats (n ϭ 5), as well as by PDGF-AB alone (100 ng/heart) in 4-mo-old rats (n ϭ 8) and 24-mo-old rats (n ϭ 10).
Survival assay of TNF-␣-treated old hearts. To investigate TNF-␣ induced mortality after LAD occlusion in the 24-moold rats, additional sets of older rats received intramyocardial injection of TNF-␣ (100 ng/heart; n ϭ 5) without subsequent coronary occlusion. These TNF-␣-treated old rats were observed for 2 wk, and the survival number was recorded.
Statistical analysis. Comparisons of categorical variables were conducted using the binomial distribution or Fisher's exact test, as appropriate. For nonnormally distributed continuous variables, a Wilcoxon rank-sum test was used. A two-tailed P value Ͻ0.05 was considered statistically significant.
RESULTS
In vivo cardiac biopanning revealed repetitive homologies to TNF-␣ in the younger but not older cardiachoming phage clones (2/101 vs. 0/100, P Ͻ 0.05) in Fig.  1, A and B . In vivo injection with individual phage colonies confirmed the diminished cardiac homing of ⌿Y12 in the old murine heart (Fig. 1C) , suggesting that the binding sites for the TNF-␣-like phage motif may be decreased in the aging cardiac microvasculature. Immunostaining of 3-and 18-mo-old hearts revealed age-associated changes in one of the TNF receptors. TNF-R2 patterning was similar in the microvasculature throughout the young and old murine hearts (Fig. 2, A and B) . Similarly, TNF-R1 was present in the microvasculature throughout the younger hearts; however, in the older hearts, the receptor was restricted to the subepicardial microvasculature, with a significantly lower density of TNF-R1 in the senescent subendocardium.
The functional significance of the changes in TNF-␣ receptor pathways in the aging cardiac microvaculature was then examined. On the basis of previous reports (12, 15) demonstrating that TNF-␣ promotes the expression of PDGF-B in endothelial cells in vitro, we hypothesized that TNF-␣ induction of PDGF-B would be impaired in the aging CMECs. In vitro stud- Fig. 2 . Aging-associated alterations in cardiac microvascular TNF-␣ receptor pathways (R1 and R2). A: representative immunostaining for TNF-R1 and -R2 in the exterior (subepicardium) and interior (subendocardium) tissue of 3-and 18-mo-old murine hearts (bar ϭ 10 m). B: TNF-R1 and two densities in the subendocardium of 3-and 18-mo-old murine hearts (n ϭ 3, each). *P Ͻ 0.01 TNF-R1 in 3-vs. 18-mo-old hearts. ies confirmed that TNF-␣ induced the expression of PDGF-B in CMECs of the 4-mo-old rat heart but not in cells from the 24-mo-old hearts, Fig. 3A . In vivo TNF-␣ specifically induced the increase of PDGF-B in the younger hearts, while having minimal effect on the aging tissue (Fig. 3, B and C) .
The functional impact of the senescent dysregulation of cardiac TNF-␣ receptor pathways resulted in a loss of cardioprotection in the aging heart. In the young heart, intramyocardial injection of TNF-␣, like PDGF-AB, markedly reduced the extent of myocardial injury induced by ligation of the LAD (Fig. 4, A and B) . In the old rats, TNF-␣ was deleterious, resulting in a high mortality rate within 72 h of coronary occlusion, which was associated with extensive myocardial apoptosis (Fig. 5, A and B) . Coinjection with PDGF-AB restored viability after coronary occlusion in the old rats (Fig.  5A ) with a reduction in myocardial infarction size compared with control injections (Fig. 4) . Combined injection of TNF-␣ and PDGF-AB in the younger rats, however, provided no increase in cardioprotection beyond injection of the individual growth factors.
DISCUSSION
In the present study, we demonstrate that senescent alterations in TNF-␣ receptor pathways contribute to cardiac microvascular dysfunction and loss of cardioprotection in the aging rodent heart. In vivo phage display studies identified a cardiac microvascularhoming TNF-␣ homologous peptide in young hearts that subsequently revealed an age-associated decrease of TNF-R1 in cardiac subendocardial microvasculature. Functional studies (10) demonstrated that this dysregulation in cardiac microvascular endothelial TNF-␣ receptor pathways contributes to the age-associated impairment in cardioprotective PDGF-B induction. Indeed, the senescent alterations in the cardiac actions of TNF-␣ resulted in increased mortality after coronary occlusion, which was reversed by the restoration of PDGF.
Previous studies (5, 8, 9, 11, 25, 35) have revealed that TNF-␣ mediates a diverse array of both beneficial and deleterious molecular and cellular cardiovascular responses. Potential protective actions of TNF-␣ include preconditioning of the ischemic heart (35), reducing hypoxic injury of cardiac myocytes (24) , enhancing angiogenic activity (23, 42) , and inducing PDGF pathways in endothelial cells (12, 15) . The pathways governing these complex multicellular responses as well as TNF-␣-mediated pathophysiology in the heart have not been fully elucidated but likely involve TNF-␣ secreted from cardiac myocytes (18, 39) regulating the function of endothelial cells expressing TNF receptors (44) . The present studies demonstrate that short-term stimulation of intact TNF-␣ receptor pathways in the young cardiac microvasculature can induce expression Fig. 4 . TNF-␣ protects the young but not old rat heart from myocardial injury after coronary occlusion. A: representative cardiac histology after coronary occlusion: Masson's trichrome staining (blue stain) for myocardial injury (14 days postcoronary occlusion) in 4-and 24-mo-old rat hearts treated with PBS control (4-and 24-mo-old, n ϭ 4 and 10, respectively), TNF-␣ (4-mo-old, n ϭ 4), PDGF-AB (4-and 24-mo-old, n ϭ 8 and 10, respectively), and TNF-␣/PDGF-AB (4-and 24-mo-old, n ϭ 5, each). Analysis of the extent of myocardial injury in TNF-␣-treated 24-moold rat hearts was not determined (ND) due to extensive mortality after coronary occlusion (Fig. 5) . ND, not determined. B: quantification of the extent of injury in the different sets of rat hearts 14 days postcoronary occlusion. In the young heart, TNF-␣, PDGF-AB, and the combination of TNF-␣ and PDGF-AB all reduced myocardial infarction size to a similar extent. Old rats pretreated with PDGF-AB and the combination of TNF-␣ and PDGF-AB were viable and had similar reductions in myocardial infarction size compared with control injections. *P Ͻ 0.05 infarction size in 4-mo-PBS vs. 4-mo-old TNF-␣, 4-mo-old PDGF-AB, and 4-mo-old TNF-␣/PDGF-AB, respectively. **P Ͻ 0.05 infarction size in 24-mo-PBS vs. 24-mo-old PDGF-AB and 24-mo-old TNF-␣/ PDGF-AB, respectively. of PDGF-B, and, more importantly, reduce the extent of myocardial injury after coronary occlusion. Indeed, the lack of synergistic actions by coinjection of TNF-␣ and PDGF in the young hearts suggests that PDGF may mediate similar or overlapping downstream signal pathways in the cardioprotection of young hearts. The age-associated dysregulation of these pathways contributes to the impairment in endothelial cell function and increases TNF-␣-induced mortality after coronary occlusion. Restoration of the PDGF-dependent downstream pathways reverses this age-associated mortality, potentially modulating apoptotic signaling cascades to promote cardioprotection in the senescent heart.
Age-associated alterations of receptor pathways and increases in cytokine levels may underlie the diminished expression of TNF-R1 and the senescent switch in the actions of TNF-␣ from cardioprotection to pathophysiology. Intracellular cofactors regulating the conformation and activity of TNF-R1 (22) may govern the function of the subpopulation of endothelial cells recognized by the ⌿Y12 motif. Senescent changes in these cofactors, with increases in TNF-receptor-associated death domain proapoptotic pathways (1, 14) , may contribute to TNF-induced apoptosis in aging endothelial cells (17) and loss of cardioprotective effects on cardiac myocytes (19, 24) . Moreover, aging is associated with chronic increases in systemic levels of TNF-␣ (4, 28) and thus could compound vascular dysfunction due to apoptosis of older endothelial cells with altered TNF-R1 signaling pathways (17) . Indeed, experimental models with sustained overexpression of TNF-␣ in the rodent heart result in marked left ventricular dysfunction and heart failure (5, 11) , and the mortality after coronary occlusion observed in the TNF-␣-treated older hearts may be due to the further enhancement of the senescent receptor pathways mediating this cardiovascular pathophysiology.
Therapies based on the cardioprotective role of TNF-␣ may have clinical utility in the younger heart, but novel strategies are required to optimize treatments of cardiovascular disease in older persons. Restoration of TNF-R1 expression in the aging cardiac microvasculature through gene therapy approaches has limited utility because the receptor itself can mediate viral-induced apoptotic pathways (16, 21, 43) . Moreover, reexpression of the receptors may enhance the TNF-␣ proapoptotic pathways in the aging heart. Repopulation of the TNF-R1 endothelial cells with autologous or genetically matched endothelial precursor cells could overcome these limitations and potentially restore senescent vascular function. Alternatively, approaches aimed a decreasing or reversing the ageassociated alterations in TNF-␣ and its receptor pathways may have significant applicability. To this end, previous studies (36) have demonstrated that estrogen protects endothelial cells from TNF-␣-induced apoptosis and may be useful in preventing the senescent loss of TNF-R1 in cardiac endothelial cells. Similarly, identification of the critical genes downstream from TNF-␣, potentially acting with PDGF-B induction, may allow for the development of cardiac-specific therapies that could have benefit for persons of all ages. Small molecules, including cyclic peptides, based on the structure and sequence of ⌿Y12, could provide novel strategies to selectively target cardioprotective pathways, potentially without the concomitant induction of apoptosis in older hearts. Moreover, such therapies could be combined with molecule approaches that are based on pathways that are upregulated in the senescent heart to develop therapies specifically tailored for the treatment and possible prevention of cardiovascular disease in older persons. Fig. 5 . Survival assay and apoptosis staining. A: 14-day survival percentage of the sets of young and old rats receiving intramyocardial injection with various combinations of PBS, TNF-␣, and PDGF-AB, with or without subsequent coronary occlusion. In the old rat heart, the combination of TNF-␣ and coronary occlusion resulted in increased mortality. Coinjection with PDGF-AB restored viability after coronary occlusion. B: terminal deoxynucleotidyl transferasemediated dUTP nick-end label staining with diaminobenzidene (DAB) (2 days postcoronary occlusion) in 24-mo-old hearts treated with TNF-␣ (n ϭ 10; 80% mortality within 2-day postcoronary occlusion vs. PBS-0%; P Ͻ 0.05) in left, and high-power micrographs (bar ϭ 10 m) in right. *P Ͻ 0.05, 24-mo-old TNF-␣-injected coronary occlusion hearts vs. other groups.
